Menu Close

Trending

AbbVie and Cugene partner to tackle autoimmune diseases
2nd Annual mRNA-Based Therapeutics Summit
BenevolentAI, AstraZeneca AI-based drug discovery collaboration achieves third milestone
Do pharmaceutical businesses need to rethink what their graduate schemes offer?
AstraZeneca extends oncology partnership with Proteros

ES-SCLC

NICE1

Market Access/ News/ News/ News/ Oncology/ Top stories

NICE recommends Roche’s Tecentriq in ES-SCLC following price rethink

, , , , , , 0 Comment

NICE has said that Roche’s Tecentriq (atezolizumab) plus chemotherapy should be funded by the NHS as an option for untreated extensive-stage small-cell

X
NICE recommends Roche’s Tecentriq in ES-SCLC following price rethink
https://pharmaphorum.com/news/nice-recommends-roches-tecentriq-in-es-sclc-following-price-rethink/

Login

CONTINUE TO SITE >
X
Close in 10 seconds